Stockscreener 앱 받기
47.98
2.19%
1.03
시장 영업 전:
47.20
-0.78
-1.63%
전일 마감가:
$46.95
열려 있는:
$47.15
하루 거래량:
422.13K
Relative Volume:
1.13
시가총액:
$2.30B
수익:
$264.38M
순이익/손실:
$-109.16M
주가수익비율:
-20.51
EPS:
-2.3395
순현금흐름:
$-39.22M
1주 성능:
+10.76%
1개월 성능:
+15.59%
6개월 성능:
+21.50%
1년 성능:
+82.23%
1일 변동 폭
$46.51
$48.66
1주일 범위
$44.15
$48.66
52주 변동 폭
$23.14
$48.89
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
47.98 | 2.30B | 264.38M | -109.16M | -39.22M | -2.3395 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharmaceuticals' chief medical officer sells $319,598 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals' chief medical officer sells $319,598 in stock - Investing.com
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results - MSN
(MIRM) Investment Report - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Purchases 29,545 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Metagenomi Announces New Appointment to its Board of Directors - The Manila Times
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Up 6%Here's What Happened - MarketBeat
Mirum Pharmaceuticals exceeds 2024 sales forecast, eyes growth By Investing.com - Investing.com Australia
Mirum Pharmaceuticals exceeds 2024 sales forecast, eyes growth - Investing.com India
Mirum Pharmaceuticals Surpasses 2024 Sales Guidance, Projects Strong 2025 Growth to $435M - StockTitan
This Insider Has Just Sold Shares In Mirum Pharmaceuticals - Simply Wall St
Mirum Pharmaceuticals Grants Stock Awards to Eight New Employees in Growth Initiative - StockTitan
Mirum Pharmaceuticals CEO sells $320,643 in stock - Investing.com India
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Mirum Pharmaceuticals president sells $85,544 in stock By Investing.com - Investing.com Canada
Jolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 1,998 Shares - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 7,489 Shares - MarketBeat
Mirum pharmaceuticals SVP Jolanda Howe sells shares worth $32,111 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals CEO sells $320,643 in stock By Investing.com - Investing.com Canada
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM) - Seeking Alpha
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Analysts Expect Breakeven For Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Before Long - Simply Wall St
(MIRM) Trading Advice - Stock Traders Daily
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Path To Profitability - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Grows Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential (NASDAQ:MIRM) - Seeking Alpha
State Street Corp Buys 297,511 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $57.73 - Defense World
Mirum Pharmaceuticals' SWOT analysis: liver disease specialist's stock poised for growth - Investing.com
Wellington Management Group LLP Has $4.77 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
741,368 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Lord Abbett & CO. LLC - MarketBeat
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea - Marketscreener.com
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $57.73 - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? - MSN
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 - BioSpace
Frazier Life Sciences Management L.P. Purchases 75,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals Awards Key Inducement Grants to Strengthen Leadership Team - StockTitan
Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues - Simply Wall St
Charles Schwab Investment Management Inc. Acquires 17,149 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):